T2	Claim 90 179	Postoperative radiochemotherapy (RCT) is recommended for advanced disease (pT3/4 or pN+).
T6	Premise 1516 1623	Acute toxicity (WHO) of RCT was low, with less than 15% of patients experiencing grade 3 or higher toxicity
T7	Premise 1625 1799	The principal toxicity was diarrhea, with 12% in the postoperative RCT-arm and 11% in the pre-operative RCT-arm having grade 3-, and 1% in either arm having grade 4-diarrhea.
T3	Premise 1800 1959	Erythema, nausea and leukopenia were the next common toxicities, with less than 3% of patients in either arm suffering grade 3 or greater leukopenia or nausea.
T4	Premise 1960 2264	Postoperative complication rates were similar in both arms, with 12% (postop. RCT) and 12% (pre-op. RCT) of patients, respectively, suffering from anastomotic leakage, 3% (postop. RCT) and 3% (pre-op. RCT) from postoperative bleeding, and 6% (postop. RCT) and 4% (pre-op. RCT) from delayed wound healing.
T5	Claim 2265 2313	The patient accrual to the trial is satisfactory
T8	Claim 2315 2402	Neoadjuvant RCT is well tolerated and bears no higher risk for postoperative morbidity.
R1	Support Arg1:T6 Arg2:T8	
R2	Support Arg1:T7 Arg2:T8	
R3	Support Arg1:T3 Arg2:T8	
R4	Support Arg1:T4 Arg2:T8	
